PATENT CLAIM ANALYSIS

Application Number: 16403176
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-08
Patent Classification: ["424", "489000"]

Abstract:
Embodiments are directed to a secnidazole formulations and the use of a secnidazole formulation for the treatment of bacterial vaginosis (BV).

Claim (Index 59):
The single dose pharmaceutical composition of  claim 53 , further comprising a therapeutically effective amount of an additional compound selected from the group consisting of ethinyl estradiol (EE2), norethindrone (NET), or a combination thereof, and wherein the therapeutically effective amount of secnidazole in the microgranule formulation does not affect the contraceptive efficacy of the additional compound selected from the group consisting of ethinyl estradiol (EE2), norethindrone (NET), or a combination thereof.

Metadata:
- Claim Count in Document: 146.0
- Percentile: 100.0
- Lexical Diversity: 1.2
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14846505', '16049032', '13472953', '15990010', '13982675']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7610408680888696
- 35 USC 102 Novelty (BERT): 0.7096376865609344
- Combined Prediction Score: 0.7559005499360761
- Mean Citation Score: 462.23057400000016
- Max Citation Score: 835.29974
- Similarity Product: 668.1387826243973

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test